Specificity of L1 peptides versus virus-like particles for detection of human papillomavirus-positive cervical lesions in females attending Engativa Hospital, Bogota, Colombia.
A serological test for the detection of human papillomavirus (HPV) infection in females at risk of developing cervical cancer could be based on conserved L1 peptides with low levels of antigenicity specifically recognized by antibodies from patients with cervical lesions infected with high-risk HPV (HR-HPV) types. The aim was to assess the ability of L1 peptides 18283, 18294, and 18301 compared with the ability of virus-like particles (VLPs) to identify these infections in females. A total of 391 HPV-infected female volunteers were interviewed, and peripheral blood and cervical cells were obtained for detection of anti-HPV antibodies and HPV DNA; all of the patients had a Pap smear test; 287 patients were referred for colposcopy or biopsy, according to gynecological criteria. The level of agreement, as determined by the use of the Lin coefficient (rho value), showed that 75 to 83% of females with HR-HPV DNA-positive cervical lesions had antibodies that recognized VLPs and peptide 18283, 18294, or 18301, while 15 to 23% of the HPV DNA-negative females with a normal cytology had antibodies that recognized these three peptides and 45% had antibodies that recognized VLPs. The rate of agreement between peptides and VLPs for antibody detection was higher for patients with HPV DNA-positive cervical lesions. Peptides 18283, 18294, and 18301 showed similar sensitivities for the detection of HR-HPV DNA-positive cervical lesions and were more specific than VLPs. Peptide 18301 might be detecting protective antibodies in HPV DNA-negative females with atypical squamous cells of undetermined significance. These peptides could be useful for the design of a serology test for the detection of HR-HPV infection in females with cervical lesions and at risk of cervical cancer.
Urquiza
Mauricio
M
Virology, Fundacion Instituto de Inmunologia de Colombia, Carrera 50, #26-00, Bogota 020304, Colombia. mauricio_urquiza@fidic.org.co
Sánchez
Ricardo
R
Amaya
Jairo
J
León
Sandra
S
Acosta
Jenny
J
Patarroyo
Manuel A
MA
Camargo
Milena
M
Patarroyo
Manuel E
ME
D000293:Adolescent; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood*; D003105:Colombia; D004279:DNA, Viral / Q000302:isolation & purification; D005260:Female; D006761:Hospitals; D006801:Humans; D007159:Immunologic Tests / Q000379:methods; D008875:Middle Aged; D065006:Papanicolaou Test; D030361:Papillomavirus Infections / Q000175:diagnosis*; D012680:Sensitivity and Specificity; D014626:Vaginal Smears; D014764:Viral Proteins; D022701:Virosomes
D000914:Antibodies, Viral; D004279:DNA, Viral; D014764:Viral Proteins; D022701:Virosomes
J Clin Microbiol. 1996 Sep;34(9):2095-100
8862564
Eur J Cancer. 1996 May;32A(5):872-6
9081369
Science. 1988 Jan 29;239(4839):487-91
2448875
J Clin Microbiol. 1998 Jul;36(7):2046-51
9650960
Int J Cancer. 1992 Feb 1;50(3):349-55
1310487
J Adolesc Health. 2005 Dec;37(6 Suppl):S3-9
16310138
J Infect Dis. 1995 Jul;172(1):19-24
7797910
J Clin Microbiol. 2000 Feb;38(2):688-95
10655368
J Infect Dis. 2000 Jun;181(6):1911-9
10837170
J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62
9049358
Biometrics. 1989 Mar;45(1):255-68
2720055
J Clin Virol. 2004 Aug;30(4):302-8
15163418
J Natl Cancer Inst. 1997 May 7;89(9):630-8
9150187
Int J Cancer. 2005 May 20;115(1):114-20
15688414
Clin Diagn Lab Immunol. 2002 May;9(3):577-82
11986263
Br J Cancer. 2004 Aug 31;91(5):942-53
15292939
J Virol. 2003 Nov;77(21):11625-32
14557648
Proc Natl Acad Sci U S A. 1985 Aug;82(15):5131-5
2410914
EMBO J. 2002 Sep 16;21(18):4754-62
12234916
J Gen Virol. 2004 Sep;85(Pt 9):2643-2650
15302958
Science. 1985 Dec 20;230(4732):1350-4
2999980
Virology. 1985 Aug;145(1):181-5
2990099
Rev Inst Med Trop Sao Paulo. 2003 May-Jun;45(3):131-5
12870061
Obstet Gynecol Surv. 2006 Jun;61(6 Suppl 1):S3-14
16729902
Gynecol Oncol. 2004 Mar;92(3):873-80
14984955
J Clin Virol. 2000 Oct;19(1-2):1-5
11091143
Asian Pac J Cancer Prev. 2001 Apr-Jun;2(2):135-141
12718645
J Infect Dis. 1996 Nov;174(5):927-36
8896492
Clin Diagn Lab Immunol. 1997 Mar;4(2):122-6
9067643
Cancer Lett. 2006 Jan 18;231(2):309-13
16399232
Cancer. 2006 Oct 25;108(5):288-97
16952155
Int J Cancer. 2002 Feb 20;97(6):796-803
11857357
J Virol. 2006 May;80(10):4664-72
16641259
J Natl Cancer Inst. 1995 Sep 20;87(18):1365-71
7658497
Dermatol Clin. 2002 Apr;20(2):315-31
12120445
Biochem Biophys Res Commun. 2005 Jun 24;332(1):224-32
15896321
J Clin Virol. 2005 Mar;32 Suppl 1:S16-24
15753008
J Infect Dis. 1998 Jun;177(6):1710-4
9607854